Critical Error in Question: These Are Completely Different Medications
There is no equivalent dose of Repatha (evolocumab) for Epoetin Alfa-epbx because these are entirely different drug classes treating completely different conditions—this question appears to be based on a fundamental misunderstanding.
Why This Question Cannot Be Answered
Epoetin Alfa-epbx is an erythropoiesis-stimulating agent (ESA) used to treat anemia by stimulating red blood cell production, typically dosed at 150 units/kg three times weekly or 40,000 units weekly subcutaneously for chemotherapy-associated anemia 1
Repatha (evolocumab) is a PCSK9 inhibitor monoclonal antibody used to lower LDL cholesterol in patients with hyperlipidemia and cardiovascular disease, dosed at 140 mg every 2 weeks or 420 mg monthly subcutaneously 1
These Medications Have No Therapeutic Overlap
Epoetin Alfa treats:
- Chemotherapy-associated anemia 1
- Targets hemoglobin levels (goal: maintain lowest level to avoid transfusions, typically 10-12 g/dL) 1
- Works by stimulating erythropoietin receptors to increase red blood cell production 1
Repatha (evolocumab) treats:
- Primary hyperlipidemia, familial hypercholesterolemia, and atherosclerotic cardiovascular disease 1
- Targets LDL cholesterol reduction (reduces LDL-C by approximately 60%) 1, 2
- Works by inhibiting PCSK9 protein to increase LDL receptor availability 1, 3
Clarification Needed
If you are treating anemia: Continue Epoetin Alfa-epbx at 10,000 units/mL weekly as prescribed, following FDA-approved dosing for ESAs 1
If you are treating hyperlipidemia: Use Repatha at standard dosing of 140 mg subcutaneously every 2 weeks or 420 mg monthly, independent of any anemia treatment 1, 2
If the patient needs both medications: They can be administered concurrently for their respective indications, as there is no pharmacologic interaction between cholesterol-lowering therapy and erythropoiesis-stimulating agents—but there is no dose conversion or equivalence between them.